Previous 10 | Next 10 |
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors will get a test next week when the consumer report index report drops on September 15 to give a read on inflat...
BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lys...
Gainers: Kadmon (NASDAQ:KDMN) +73%. ICU Medical (NASDAQ:ICUI) +32%. Candel Therapeutics (NASDAQ:CADL) +23%. Globalstar (NYSE:GSAT) +22%. Spectrum Brands (NYSE:SPB) +20%. Vinco Ventures (NASDAQ:BBIG) +19%. WISeKey (NASDAQ:WKEY) +14%. SilverBow (NYSE:SBOW) +16%. Aterian (NASDAQ:ATER) +16%. Gain...
Gainers: Kadmon KDMN +73%, ICU Medical ICUI +32%, Candel Therapeutics CADL +17%, Gain Therapeutics GANX +9%, Concord Medical Services (NYSE:CCM) +9%. Losers: INmune Bio (NASDAQ:INMB) -22%, Inozyme Pharma (NASDAQ:INZY) -19%, Alector A...
Kadmon Holdings (NASDAQ:KDMN) +74% Sanofi strengthens transplant business with acquisition of Kadmon for $1.9B Gain Therapeutics (NASDAQ:GANX) +27% on positive GT-02287and GT-02329 data in Parkinson’s disease Alset EHome International (NASDAQ:AEI) +15% inv...
GT-02287and GT-02329 compounds display positive effects on GCase activity and related parameters --- Study results demonstrate an increase in GCase protein levels with transport to the lysosomes and decrease of glucosylceramide and α-synuclein-p129 levels --- ...
David Einhorn's 13F stock portfolio value increased from $1.44B to $1.59B this quarter. Greenlight increased Teck Resources, GoPro, and The ODP Corp while reducing APi Group, CNX Resources, and Katapult Holdings during the quarter. They also dropped ADT Inc. and Alight Inc. The la...
BETHESDA, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lys...
Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with ...
Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology --- Granted Two Patents for Compounds that Stabilize G-Case for Gaucher's Disease and other Synucleinopathies including Parkinson's Disease, Lewy Body Dementia and Alzheimer’s Dise...
News, Short Squeeze, Breakout and More Instantly...
Gain Therapeutics Inc. Company Name:
GANX Stock Symbol:
NASDAQ Market:
Gain Therapeutics Inc. Website:
GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in Parkinson’s Disease Patients in Q4 2024 BETHESDA, Md., July 09, 2024 (GLOBE NEWSW...
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announc...